Entrada Therapeutics Overview
Latest P/E ratio for Entrada Therapeutics: -1.7 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-1.70
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for TRDA is -1.7. That is below the sector sector average of 44.85. Investors often review this figure alongside Entrada Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, TRDA currently prints -1.7 for P/E ratio, while the sector average sits near 44.85. That is roughly 103.8% below the sector mean. Large gaps often invite a closer look at Entrada Therapeutics's growth, margins, and balance sheet.
A P/E ratio of -1.7 for Entrada Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (44.85) and with TRDA's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting TRDA's P/E ratio (-1.7), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
